- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01704365
RSV-F Vaccine Dose Ranging Study in Young Women
A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- Anaheim Clinical Trials
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Accelovance Rockville
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Coastal Carolina Research
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult females, ≥ 18 and ≤ 35 years of age. "Healthy" shall be defined by the absence of any illness, acute or chronic, that requires ongoing systemic therapy for the control of symptoms or prevention of disability.
- Subjects on stable (no change in ≥ 3 months) therapy for findings (e.g., hypertension or hyperlipidemia) that are not associated with symptoms or disability are eligible, as are users of hormonal contraceptives.
- Subjects who receive intermittent prophylaxis for risks associated with asymptomatic findings (e.g., antibiotic prophylaxis prior to dental procedures in a subject with mitral valve prolapse) are eligible.
- Ongoing therapy will be defined as continuous or, if intermittent, more frequent than once every 3 months (e.g., use of an inhaled bronchodilator for exercise-induced bronchospasm more than once every 3 months). Immunosuppressives are subject to exclusion criterion #5 below.
- Persons being treated for illnesses or conditions that would become acutely symptomatic or disabling in the absence of treatment are not eligible.
- Willing and able to give informed consent prior to study enrollment.
- Able to comply with study requirements.
- Women who are not surgically sterile must have a negative urine pregnancy test prior to each vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and IUD.
Exclusion Criteria:
- Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
- History of a serious reaction to any prior vaccination.
- Received any vaccine in the 4 weeks preceding the study vaccination; or any RSV vaccine at any time.
- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
- Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
- Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration).
- Known disturbance of coagulation.
- Women who are pregnant or breastfeeding, or plan to become pregnant during the study.
- Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
- Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
|
0.5mL IM Injection
|
Experimental: Group B
Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
|
0.5mL IM Injection
0.5mL IM Injection
|
Experimental: Group C
Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
|
0.5ml IM Injection
|
Experimental: Group D
Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
|
0.5mL IM Injection
0.5ml IM Injection
|
Experimental: Group E
High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
|
0.5mL IM Injection
|
Experimental: Group F
High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
|
0.5mL IM Injection
0.5mL IM Injection
|
Experimental: Group G
High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
|
0.5mL IM Injection
|
Experimental: Group H
High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
|
0.5mL IM Injection
0.5mL IM Injection
|
Experimental: Group J
Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
|
0.5mL IM Injection
|
Placebo Comparator: Group K
Placebo (Day 0 and Day 28)
|
0.5mL IM Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groups
Time Frame: Day 0 to Day 112
|
Immunogenicity will be measured using derived / calculated endpoints based on:
|
Day 0 to Day 112
|
Assessment of the safety
Time Frame: Day 0 to Day 182
|
Number (and percentage) of subjects with solicited local and systemic Adverse Events over the seven days post-injections; all adverse events, solicited and unsolicited over 56 days post-first injection. Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for six months |
Day 0 to Day 182
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity based on neturalizing antibody titer
Time Frame: Day 0 to Day 112
|
Day 0 to Day 112
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NVX757.201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Syncytial Virus (RSV)
-
University of RochesterActive, not recruitingRespiratory Syncytial Virus (RSV)United States
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in...Active, not recruitingRespiratory Syncytial Virus (RSV)United Kingdom
-
Enanta Pharmaceuticals, IncCompletedRespiratory Syncytial Virus (RSV)United States
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus (RSV)Belgium
-
Enanta Pharmaceuticals, IncRecruitingRespiratory Syncytial Virus (RSV)United States, Spain, Israel, Australia, Germany, Korea, Republic of, Taiwan, United Kingdom, Argentina, Brazil, New Zealand, Poland, Romania, South Africa, Mexico
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
-
VaxartCompletedRespiratory Syncytial Virus (RSV)United States
-
PfizerCompletedRESPIRATORY SYNCYTIAL VIRUS (RSV)United States
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
Clinical Trials on Low dose RSV-F Vaccine with Adjuvant
-
NovavaxCompletedRespiratory Syncytial Virus (RSV)United States
-
NovavaxCompleted
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States, Belgium
-
VaxartCompletedRespiratory Syncytial Virus (RSV)United States
-
NovavaxBill and Melinda Gates FoundationCompletedRespiratory Syncytial Virus InfectionsUnited States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
-
NovavaxCompletedRespiratory Syncytial Virus InfectionsUnited States
-
NovavaxCompletedRespiratory Synctial VirusCanada
-
Medigen Vaccine Biologics Corp.CompletedH7N9 Influenza VaccineTaiwan
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus (RSV)Belgium
-
NovavaxCompleted